Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. 

Biotechnology

Bolt Biotherapeutics

Randall Schatzman

Dawn Colburn

Senita Greene

Willie Quinn

Lynn Ferguson Lewis

Geoff W.

Aldwin Aldana Ms, Rqap-Glp, Mrqa

Pam Howland

Tai Yu

Nathan Ihle

Grant Yonehiro

Michael N. Alonso

Wesley Burwell

Lu Xu

John Tomaro

Sarah Nemec

Edith A. Perez

The executive team at Bolt Biotherapeutics has a history of experience in the development, early stages, and clinical pharmacology of oncology drugs. They also have a wide range of experience in different aspects of the pharmaceutical industry, including immuno-oncology, coagulation, and bleeding.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at Bolt Biotherapeutics

Board of Directors

Leadership Team